Other languages Checkpoint Therapeutics, Inc.

Equities

CKPT

US1628282063

Delayed Nasdaq Other stock markets 01:30:00 08/05/2024 am IST			5-day change	1st Jan Change
1.69 ^USD	+3.68%		+21.58%	-26.20%

22/03	Checkpoint Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
18/03	Checkpoint Therapeutics, Inc. Appoints Amit Sharma to Its Board as an Independent, Non-Executive Director	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Checkpoint Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03
Checkpoint Therapeutics, Inc. Appoints Amit Sharma to Its Board as an Independent, Non-Executive Director	18/03
Checkpoint Therapeutics Launches $14 Million Registered Direct Offering	29/01
U.S. Food and Drug Administration Issues Complete Response Letter for Checkpoint Therapeutics, Inc.'s Cosibelimab Solely Due to Inspection Findings At Third-Party Manufacturer	18/12
US FDA declines to approve Checkpoint Therapeutics' skin cancer therapy	18/12
Checkpoint Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer	18/23/18
Checkpoint Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15
Checkpoint Therapeutics to Raise $10 Million in Offering of Shares, Warrants; Stock Falls	31/23/31
Checkpoint Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16
Checkpoint Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	01/23/01
Top Midday Decliners	31/23/31
Checkpoint Therapeutics to Raise $6.1 Million via Registered Direct Offering	31/23/31
Checkpoint Therapeutics Files $150 Million Mixed Shelf	27/23/27
Checkpoint Therapeutics Says US FDA Accepted Biologics License Application for Potential Skin Cancer Treatment	02/23/02
Checkpoint Therapeutics Announces FDA Filing Acceptance of Biologics License Application for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma	02/23/02
Checkpoint Therapeutics Submits Biologics License Application for Skin Cancer Therapy	04/23/04
Checkpoint Therapeutics, Inc. Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma	04/23/04
Checkpoint Therapeutics to Effect 1-For-10 Reverse Stock Split; Shares Tumble After Hours	06/22/06
Checkpoint Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	09/22/09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Checkpoint Therapeutics, Inc.

Equities

CKPT

US1628282063

Other languages

Filters